Stoke Therapeutics (STOK) Net Income towards Common Stockholders (2018 - 2026)

Stoke Therapeutics' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at -$50.0 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 144.3% year-over-year to -$50.0 million; the TTM figure through Mar 2026 stood at -$174.3 million (down 478.76% YoY), while the FY2025 annual figure was -$204.3 million, down 67.55% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$50.0 million, up from -$62.4 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $112.9 million in Q1 2025, with the low at -$162.8 million in Q4 2023.
• The 5-year median for Net Income towards Common Stockholders is -$27.2 million (2023), against an average of -$36.4 million.
• Peak annual rise in Net Income towards Common Stockholders reached 527.99% in 2025, while the deepest fall reached 323.5% in 2025.
• Stoke Therapeutics' Net Income towards Common Stockholders stood at -$124.5 million in 2022, then tumbled by 30.69% to -$162.8 million in 2023, then jumped by 90.94% to -$14.7 million in 2024, then plunged by 323.5% to -$62.4 million in 2025, then increased by 19.91% to -$50.0 million in 2026.
• Business Quant data shows STOK's Net Income towards Common Stockholders at -$50.0 million in Q1 2026, -$62.4 million in Q4 2025, and -$38.3 million in Q3 2025.